Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

RIGLBullishResearch Analysisnews

High materiality8/10

Rigel's Pralsetinib Shows Broad RET Fusion Activity Across Tumors at ESMO

Oct 19, 2026, 6:00 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong ORR signals across multiple RET-fusion tumor types and first-line NSCLC suggest meaningful clinical and commercial upside, especially if sustained; however, small cohorts and reliance on pooled analyses temper expectations.

AI summary

What happened, with direct paths to the underlying reporting

Rigel announced pooled ARROW/TAPISTRY data for pralsetinib (GAVRETO) with a 53% ORR across RET fusion solid tumors and strong thyroid/pancreatic signals. First-line NSCLC results (75% ORR) bolster potential tumor-agnostic and front-line use. Data to be presented at ESMO 2026 could impact valuation if safety and durability hold.

ORR 53% across 49 RET-fusion solid tumors; DOR 12.2 months.
Pancreatic subset ORR 88% (7/8) in previously treated patients.
Thyroid cancer ORR 81.3% in TAPISTRY.
NSCLC ARROW first-line ORR 75% vs 26% after.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Rigel's Pralsetinib Shows Broad RET Fusion Activity Across Tumors at ESMO

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential